Format

Send to

Choose Destination
Oncotarget. 2015 Apr 10;6(10):7727-40.

TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.

Author information

1
Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore 138672, Singapore.
2
Bone Tumor Reference Center at The Institute of Pathology, University Hospital Basel, CH-4003 Basel, Switzerland.
3
Clinical Cooperation Group Osteosarcoma, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany.
4
Department of Pediatrics and Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
5
Duke-NUS Graduate Medical School Singapore, Singapore 169857, Singapore.
6
Institute for Genomic Medicine, UC San Diego, La Jolla, CA 92830, USA.
7
Huntsman Cancer Institute, University of Utah Health Care, Utah, UT 84112, USA.
8
Computational & Systems Biology, Genome Institute of Singapore, Singapore 138672, Singapore.
9
Personal Genomics Solutions, Genome Institute of Singapore, Singapore 138672, Singapore.
10
Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore.
11
Department of Pediatrics and Wilhelm Sander Sarcoma Treatment Unit, Technische Universität München and Pediatric Oncology Center, 81675 Munich, Germany.
12
School of Computing, National University of Singapore, Singapore 117417, Singapore.

Abstract

Somatic mutations of TP53 are among the most common in cancer and germline mutations of TP53 (usually missense) can cause Li-Fraumeni syndrome (LFS). Recently, recurrent genomic rearrangements in intron 1 of TP53 have been described in osteosarcoma (OS), a highly malignant neoplasm of bone belonging to the spectrum of LFS tumors. Using whole-genome sequencing of OS, we found features of TP53 intron 1 rearrangements suggesting a unique mechanism correlated with transcription. Screening of 288 OS and 1,090 tumors of other types revealed evidence for TP53 rearrangements in 46 (16%) OS, while none were detected in other tumor types, indicating this rearrangement to be highly specific to OS. We revisited a four-generation LFS family where no TP53 mutation had been identified and found a 445 kb inversion spanning from the TP53 intron 1 towards the centromere. The inversion segregated with tumors in the LFS family. Cancers in this family had loss of heterozygosity, retaining the rearranged allele and resulting in TP53 expression loss. In conclusion, intron 1 rearrangements cause p53-driven malignancies by both germline and somatic mechanisms and provide an important mechanism of TP53 inactivation in LFS, which might in part explain the diagnostic gap of formerly classified "TP53 wild-type" LFS.

KEYWORDS:

Li-Fraumeni syndrome; TP53; cancer genomics; osteosarcoma; structural variations

PMID:
25762628
PMCID:
PMC4480712
DOI:
10.18632/oncotarget.3115
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center